FDA Focusing On Drug Shortage Risks From Puerto Rico Hurricane
Executive Summary
FDA has identified more than 40 high-priority drug products from at least five companies and is offering assistance to resume operations, including 'coordinating transport of certain critical drugs out of Puerto Rico.'
You may also be interested in...
Greater US FDA And Manufacturer Transparency Recommended As Key to Supply Chain Resilience
Manufacturers could risk losing FDA product approvals if they fail to publicize sourcing and quality information, under new proposals. National Academies expert panel says supply chain transparency – not a pandemic-induced rush to onshoring requirements – provides the framework to mitigate against and respond to drug shortages.
Coronavirus Not Impacting Rx Manufacturing Supply Chain – Yet
US FDA’s drug shortage team continues to check in with sponsors, but so far the infections and quarantines have not impacted drug production.
FDA Shortages Task Force Looks More Broadly To Tackle Root Causes
FDA’s latest drug shortages task force aims to encourage investment in the reliable manufacture of generic sterile injectables that are fundamental to the practice of medicine. While the agency’s first task force continues to work with industry to avert shortages, the second will strike at underlying structural issues that cause persistent shortages of these critical medicines.